Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Innate Immun ; 27(4): 294-312, 2021 05.
Article in English | MEDLINE | ID: mdl-34000873

ABSTRACT

In China, baicalin is the main active component of Scutellaria baicalensis, which has been used in the treatment of inflammation-related diseases, such as inflammation-induced acute lung injury. However, its specific mechanism remains unclear. This study examined the protective effect of baicalin on LPS-induced inflammation injury of alveolar epithelial cell line A549 and explored its protective mechanism. Compared with the LPS-induced group, the proliferation inhibition rates of alveolar type II epithelial cell line A549 intervened by different concentrations of baicalin decreased significantly, as did the levels of inflammatory factors IL-6, IL-1ß, prostaglandin 2 and TNF-α in the supernatant. The expression levels of inflammatory proteins inducible NO synthase (iNOS), NF-κB65, phosphorylated ERK (p-ERK1/2), and phosphorylated c-Jun N-terminal kinase (p-JNK1) significantly decreased, as did the protein expression of follistatin-like protein 1 (FSTL1). In contrast, expression of miR-200b-3p significantly increased in a dose-dependent manner. These results suggested that baicalin could significantly inhibit the expression of inflammation-related proteins and improve LPS-induced inflammatory injury in alveolar type II epithelial cells. The mechanism may be related to the inhibition of ERK/JNK inflammatory pathway activation by increasing the expression of miR-200b-3p. Thus, FSTL1 is the regulatory target of miR-200b-3p.


Subject(s)
Epithelial Cells/drug effects , Epithelial Cells/pathology , Flavonoids/therapeutic use , Follistatin-Related Proteins/drug effects , Lipopolysaccharides , MicroRNAs/biosynthesis , Pulmonary Alveoli/injuries , Signal Transduction/drug effects , A549 Cells , Cell Proliferation/drug effects , Dose-Response Relationship, Drug , Humans , Inflammation/chemically induced , Inflammation/pathology , Inflammation Mediators/metabolism , MAP Kinase Signaling System/drug effects , MicroRNAs/drug effects , MicroRNAs/genetics , Pulmonary Alveoli/drug effects , Pulmonary Alveoli/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...